{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:07:21Z","timestamp":1790485641602,"version":"4.1.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic migraine is an under-recognized and under-treated disorder. A greater understanding of the pathophysiology of migraine and transformation to chronic migraine has led to the first targeted treatments for chronic migraine. In this review, we review current approaches to the diagnosis and management of chronic migraine and discuss recent and emerging novel therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this study was to provide an update on the diagnosis and management of chronic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Material:<\/jats:title>\n                    <jats:p>The PubMed database was searched for relevant articles published on or before October 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusions:<\/jats:title>\n                    <jats:p>Chronic migraine is an under-recognized and under-treated disorder. Prompt diagnosis and appropriate management can lead to a significant improvement in the quality of life with subsequent socioeconomic benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.315972","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T04:19:32Z","timestamp":1621138772000},"page":"S67-S75","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Chronic Migraine"],"prefix":"10.4103","volume":"69","author":[{"given":"Catriona L","family":"Gribbin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna A","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20240907","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1177\/0333102420944842","article-title":"The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany","volume":"40","author":"Seddik","year":"2020","journal-title":"Cephalalgia"},{"key":"R3-9-20240907","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","article-title":"Cost of healthcare for patients with migraine in five European countries: Results from the International Burden of Migraine Study (IBMS)","volume":"13","author":"Bloudek","year":"2012","journal-title":"J Headache Pain"},{"key":"R4-9-20240907","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10194-012-0480-3","article-title":"Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples","volume":"13","author":"Teixeira","year":"2012","journal-title":"J Headache Pain"},{"key":"R5-9-20240907","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(04)00855-5","article-title":"Barriers to headache care in India and efforts to improve the situation","volume":"3","author":"Ravishankar","year":"2004","journal-title":"Lancet Neurol"},{"key":"R6-9-20240907","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","article-title":"The pathophysiology of migraine: Implications for clinical management","volume":"17","author":"Charles","year":"2018","journal-title":"Lancet Neurol"},{"key":"R7-9-20240907","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R8-9-20240907","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neuroscience.2016.04.046","article-title":"Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies","volume":"328","author":"Miller","year":"2016","journal-title":"Neuroscience"},{"key":"R9-9-20240907","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology"},{"key":"R10-9-20240907","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1526-4610.2007.00853.x","article-title":"Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies","volume":"47","author":"Aurora","year":"2007","journal-title":"Headache"},{"key":"R11-9-20240907","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R12-9-20240907","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2174\/187152708787122932","article-title":"Central sensitisation phenomena in primary headaches: Overview of a preventive therapeutic approach","volume":"7","author":"de Tommaso","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R13-9-20240907","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-4610.1987.hed2702102.x","article-title":"Transformed or evolutive migraine","volume":"27","author":"Mathew","year":"1987","journal-title":"Headache"},{"key":"R14-9-20240907","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","article-title":"Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS)","volume":"51","author":"Stokes","year":"2011","journal-title":"Headache"},{"key":"R15-9-20240907","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0333102416636055","article-title":"When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month","volume":"37","author":"Torres-Ferr\u00fas","year":"2017","journal-title":"Cephalalgia"},{"key":"R16-9-20240907","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3399\/bjgp08X376203","article-title":"Imaging patients with suspected brain tumour: Guidance for primary care","volume":"58","author":"Kernick","year":"2008","journal-title":"Br J Gen Pract"},{"key":"R18-9-20240907","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.282.1.36","article-title":"Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers","volume":"282","author":"Katzman","year":"1999","journal-title":"JAMA"},{"key":"R19-9-20240907","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/jnnp.2004.057851","article-title":"Are investigations anxiolytic or anxiogenic? A randomised controlled trial of neuroimaging to provide reassurance in chronic daily headache","volume":"76","author":"Howard","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-9-20240907","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.4103\/0972-2327.100011","article-title":"New daily persistent headache","volume":"15","author":"Tyagi","year":"2012","journal-title":"Ann Indian Acad Neurol"},{"key":"R21-9-20240907","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1001\/jama.284.20.2599","article-title":"Stratified care vs step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial","volume":"284","author":"Lipton","year":"2000","journal-title":"JAMA"},{"key":"R22-9-20240907","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1468-2982.1988.0803113.x","article-title":"The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine","volume":"8","author":"Tokola","year":"1988","journal-title":"Cephalalgia"},{"key":"R23-9-20240907","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00228-019-02748-4","article-title":"Efficacy of triptans for the treatment of acute migraines: A quantitative comparison based on the dose-effect and time-course characteristics","volume":"75","author":"Hou","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-9-20240907","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD Study: Evaluating the comparative effectiveness of onabotulinumtoxina and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"R25-9-20240907","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1468-2982.1991.1104193.x","article-title":"Propranolol in the treatment of acute migraine attacks","volume":"11","author":"Banerjee","year":"1991","journal-title":"Cephalalgia"},{"key":"R26-9-20240907","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner","year":"2014","journal-title":"Cephalalgia"},{"key":"R27-9-20240907","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1468-2982.2002.t01-1-00309.x","article-title":"Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily","volume":"22","author":"Diener","year":"2002","journal-title":"Cephalalgia"},{"key":"R28-9-20240907","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1368-5031.2005.00612.x","article-title":"Topiramate 100 mg\/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials","volume":"59","author":"Bussone","year":"2005","journal-title":"Int J Clin Pract"},{"key":"R29-9-20240907","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","article-title":"Amitriptyline in migraine prophylaxis","volume":"36","author":"Couch","year":"1979","journal-title":"Arch Neurol"},{"key":"R30-9-20240907","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","article-title":"Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs","volume":"31","author":"Dodick","year":"2009","journal-title":"Clin Ther"},{"key":"R31-9-20240907","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"R32-9-20240907","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"R33-9-20240907","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","article-title":"Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures","volume":"49","author":"Silberstein","year":"2009","journal-title":"Headache"},{"key":"R34-9-20240907","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"R35-9-20240907","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"R36-9-20240907","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","article-title":"Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial","volume":"372","author":"Ho","year":"2008","journal-title":"Lancet"},{"key":"R37-9-20240907","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"R38-9-20240907","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol"},{"key":"R39-9-20240907","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"R40-9-20240907","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"R41-9-20240907","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies-Successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R42-9-20240907","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R43-9-20240907","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R44-9-20240907","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R45-9-20240907","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"R46-9-20240907","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"R47-9-20240907","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"R48-9-20240907","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R49-9-20240907","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-9-20240907","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R51-9-20240907","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"R52-9-20240907","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"R53-9-20240907","first-page":"2515816320964401","article-title":"Role of greater occipital nerve block for preventive treatment of chronic migraine: A critical review","volume":"3","author":"Chowdhury","year":"2020","journal-title":"Cephalalgia Rep"},{"key":"R54-9-20240907","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","article-title":"Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial","volume":"80","author":"Schoenen","year":"2013","journal-title":"Neurology"},{"key":"R55-9-20240907","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0333102418811573","article-title":"Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial","volume":"39","author":"Chou","year":"2019","journal-title":"Cephalalgia"},{"key":"R56-9-20240907","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(10)70054-5","article-title":"Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial","volume":"9","author":"Lipton","year":"2010","journal-title":"Lancet Neurol"},{"key":"R57-9-20240907","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000002918","article-title":"Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study","volume":"87","author":"Silberstein","year":"2016","journal-title":"Neurology"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:14:27Z","timestamp":1787843667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315972"}},"subtitle":["An Update on Diagnosis and Management"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.315972","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}